Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management

摘要

Background. Oligometastatic stage IV non-small lung cancer (NSCLC) patients have a 5-year overall survival of 30 versus 4 to 6 in historical cohorts of stage IV NSCLC patients. We reviewed data and patterns of care of patients affected by oligometastatic NSCLC in our center between 2001 and 2017.